Crowdonomics
WatchlistPortfolio
This isn’t CODAWORX’s most recent raise. Private · Aug 2024 (Closed) is more current.View latest round
CODAWORX

Reg CF · Preferred Stock · Jul 2023

ClosedReached targetReg CFPreferred Equity
via WeFunderView campaign
Raised
$146.6K / $400K max
37% of ceiling · target hit day 5
Investors
92
$1.6K avg
Post-money valuation
$9.7M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$139K$69K$0
89450
Jul 20, 2023 · openedApr 28, 2024 · last reading
Target ($100K) hit — Jul 25, 2023, day 5Deadline Apr 29, 2024 — 1 days out

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via WeFunder; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2021–FY2022 · hover for source
$544K
−$260K
FY2021
$762K
−$432K
FY2022
RevenueNet income
Metric
FY2021 reviewed
FY2022 reviewed
Income statement
Revenue
$543,695
$761,662
Cost of goods sold
$133,124
$348,291
Gross margin
76%
54%
Net income
-$260,269
-$431,720
Taxes paid
$0
$0
Balance sheet
Cash
$154,633
$230
Accounts receivable
$6,750
$5,000
Total assets
$275,189
$80,057
Short-term debt
$275,092
$542,323
Long-term debt
$811,007
$790,151
Total liabilities
$1,086,099
$1,332,474
Other
Headcount
—
6

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Pre-money$9.5M
Post-money$9.7M
Price / share$0.6965
Shares offered143,576

Offering details

Target$100,000
Max$400,000
Min investment$100
OpenedJul 20, 2023
DeadlineApr 29, 2024
ClosedApr 30, 2024
Days active285

Links & provenance

Campaign pageSEC filing
Source: Manual
0001670254-23-000713

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.